{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:28:33Z","timestamp":1779154113333,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objective<\/jats:title><jats:p>This study compared the clinical outcomes of severe asthmatics treated with mepolizumab and benralizumab in a tertiary care severe asthma service setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient data at baseline, six and 12\u2009months were collected prospectively at two large tertiary hospital severe asthma clinics following treatment initiation. Two hundred and four patients received treatment with mepolizumab (117) or benralizumab (87). Baseline characteristics between groups were similar in regard to age, gender, body mass index, steroid dose and blood eosinophil count. However, the mepolizumab cohort had a higher Asthma Control Questionnaire Score (ACQ) at baseline (4.0\u2009\u00b1\u20091.1 vs. 3.6\u2009\u00b1\u20090.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.018), accompanied by more frequent reliever medication usage and lower prebronchodilator FEV<jats:sub>1<\/jats:sub>% (56.0\u2009\u00b1\u200920.1 vs. 63.8\u2009\u00b1\u200918.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.008).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 6\u2009months treatment, both treatments induced significant improvements in (i) ACQ of 2.3\u2009\u00b1\u20090.1 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), (ii) oral steroid requiring exacerbations (incident rate ratio 0.26 (0.18\u20130.37), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and (iii) FEV<jats:sub>1<\/jats:sub>. However, the improvement in FEV<jats:sub>1<\/jats:sub> was 0.18 (0.05\u20130.30) litres greater with benralizumab than with mepolizumab (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) even when adjusting statistically for baseline differences between groups. These differences were even more pronounced at 12\u2009months post\u2010treatment initiation, when the improvement in exacerbation frequency with benralizumab was 64% greater than with mepolizumab (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). Whilst both treatments significantly reduced the blood eosinophil count at 6 and 12\u2009months, this reduction was substantially greater with benralizumab than mepolizumab (\u2212260 cells\/\u03bcL [\u2212400 to \u2212110, <jats:italic>p<\/jats:italic>\u2009=\u20090.001]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this large group of severe eosinophilic asthmatics, mepolizumab and benralizumab both improved disease parameters. However, benralizumab treatment appeared significantly more effective than mepolizumab in reducing exacerbations, improving FEV<jats:sub>1<\/jats:sub> and depleting blood eosinophils.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.14578","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:58:05Z","timestamp":1693227485000},"page":"1117-1125","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-1766","authenticated-orcid":false,"given":"David","family":"Langton","sequence":"first","affiliation":[{"name":"Department of Thoracic Medicine Peninsula Health  Melbourne Victoria Australia"},{"name":"Peninsula Clinical School, Faculty of Medicine, Nursing and Health Sciences Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Politis","sequence":"additional","affiliation":[{"name":"Monash Lung Sleep Allergy &amp; Immunology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taya","family":"Collyer","sequence":"additional","affiliation":[{"name":"Peninsula Clinical School, Faculty of Medicine, Nursing and Health Sciences Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su\u2010Wei","family":"Khung","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine Peninsula Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-574X","authenticated-orcid":false,"given":"Philip","family":"Bardin","sequence":"additional","affiliation":[{"name":"Monash Lung Sleep Allergy &amp; Immunology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00634-2017"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa140329"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00151-2020"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S297273"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4839230"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01393-2018"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.031"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S319572"},{"key":"e_1_2_10_15_1","unstructured":"Australian Government Services Australia.Severe asthma\u2014adolescent and adult initial and recommencement after 12 months break authority application form.2021[accessed 2021 Oct 20] Available from:https:\/\/www.servicesaustralia.gov.au\/organisations\/health\u2010professionals\/forms\/pb075"},{"key":"e_1_2_10_16_1","unstructured":"Department of Health Australia.The pharmaceutical benefits scheme (PBS): benralizumab.2021[accessed 2021 Oct 20] Available from:https:\/\/www.pbs.gov.au\/medicine\/item\/11504L-11523L-11529T-11549W"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.21.1.171"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0137-2019"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax\u20102020\u2010btsabstracts.246"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032455"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14693"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13403"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.14578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T13:41:57Z","timestamp":1702042917000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.14578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/resp.14578"],"URL":"https:\/\/doi.org\/10.1111\/resp.14578","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"2023-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}